Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.
Details